Two new option listings and four option delistings on February 26th » 08:3002/2602/26/20
GNPX, SDGR, SNCA
New option listings for…
New option listings for February 26th include Genprex Inc (GNPX) and Schrodinger Inc (SDGR). Option delistings effective February 26th include Nobilis Health Corporation (NRTSF), PowerShares S&P 500 (PHDG), Seneca Biopharma (SNCA), and Ultra Petroleum Corporation (UPLC).
|Over a week ago|
Genprex, University of Pittsburgh sign exclusive license agreement » 09:0802/1102/11/20
Genprex announced that it…
Genprex announced that it signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population. Genprex plans to pursue potential partnerships for the development of this therapy globally and in the U.S.
Genprex regains compliance with Nasdaq » 08:2302/0602/06/20
Genprex announced that it…
Genprex announced that it received notice from Nasdaq indicating that the xompany has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on Nasdaq. Accordingly, the company has regained compliance with the bid price rule and Nasdaq considers the matter closed.
Genprex says TUSC2 could be novel target, biomarker for thyroid cancer » 08:2701/2901/29/20
Genprex announced that…
Genprex announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex's Oncoprex immunogene therapy, is a potential target and biomarker for thyroid carcinoma. Genprex has no affiliation with these researchers. Published in the International Journal of Molecular Sciences, the study reports that TUSC2 overexpression decreased thyroid cancer proliferation, migration and invasion. Cell proliferation, migration and invasion ability are essential steps in tumor metastasis. TUSC2 forced expression reduced thyroid cancer cell proliferation and could represent a tool to arrest cancer cell proliferation, while TUSC2 restoration decreased the migration and invasion of thyroid cancer cell lines. The study also found that TUSC2 increased sensitivity to apoptosis by increasing the SMAC/DIABLO and Cytochrome C proteins, which play major roles in apoptosis. TUSC2 forced expression increased these protein levels, and, inversely, the silencing of TUSC2 induced resistance to apoptosis. Based on the results of the study, researchers concluded that TUSC2 is negatively associated with thyroid cancer aggressiveness and, thus could be a novel target and biomarker for thyroid cancer therapy. The authors further state that thyroid carcinoma is the most common endocrine cancer and includes many different forms. Anaplastic thyroid carcinoma is the rarest but most lethal subtype.
|Over a month ago|
Genprex to host special shareholder meeting » 08:5901/2701/27/20
Special Shareholder Meeting to consider and vote on an amendment of the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock will be held in Austin, Texas on January 27 at 3:30 pm.
Sabby Management reports 6.84% passive stake in Genprex » 15:4201/2301/23/20
In a regulatory filing,…
In a regulatory filing, Sabby Management disclosed a 6.84% stake in Genprex, which represents 1.905M shares. The filing does not allow for activism.
Genprex receives fast track designation for Oncoprex from FDA » 08:0301/2101/21/20
Genprex announced that…
Genprex announced that the FDA has granted fast track designation for Genprex's Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib for the treatment of non-small cell lung cancer, or NSCLC, patients with EFGR mutations that progressed after treatment with osimertinib alone. Oncoprex is comprised of the Tumor Suppressor Candidate 2 gene, or TUSC2, complexed with a lipid nanoparticle. TUSC2 is the active agent in Oncoprex. Genprex has treated more than 50 lung cancer patients with Oncoprex in Phase I and II clinical trials. The company believes the data from these trials are encouraging as to both safety and efficacy.
Genprex files to sell 3.61M shares of common stock for holders 17:2912/2712/27/19
Genprex files automatic mixed securities shelf 17:2612/2712/27/19
|Over a quarter ago|
Genprex annoucnes $1.26M registered direct offering » 11:2011/2011/20/19
Genprex announced a…
Genprex announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of 40c per share, for gross proceeds of approximately $1.26M prior to deduction of commissions and offering expenses payable by Genprex. In a concurrent private placement, the company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 3,167,986 shares of the company's common stock. Joseph Gunnar & Co. is acting as the exclusive placement agent. The company intends to use the net proceeds of the offering for working capital and general corporate purposes. The closing of the offering is expected to take place on or about November 25, subject to the satisfaction or waiver of customary closing conditions.